Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | ECE2 | P0DPD6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20574809 | 0.92 | HTR7 (0.32) | HTR7CHRM4PDE4BECE2 | |
| SCHEMBL20576484 | 0.89 | MEN1 (0.33) | ECE2 | |
| SCHEMBL20576410 | 0.88 | ECE2 (0.30) | ECE2 | |
| SCHEMBL20575642 | 0.88 | MEN1 (0.33) | — | |
| SCHEMBL20575615 | 0.86 | HTT (0.31) | ECE2 | |
| SCHEMBL20575582 | 0.85 | — | — | |
| SCHEMBL20575188 | 0.84 | SLC6A2 (0.34) | HTR7 | |
| SCHEMBL20575631 | 0.84 | FLT3 (0.36) | ECE2 | |
| SCHEMBL20575355 | 0.84 | KDM4E (0.33) | ECE2 | |
| SCHEMBL20575524 | 0.84 | ECE2 (0.30) | ECE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | TGFBR1, TGFBR2, SMAD3 | HTR7 3955/4885CHRM4 1707/4885PDE4B 502/4885 |
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | TGFBR1, TGFBR2, SMAD3 | HTR7 3955/4885CHRM4 1707/4885PDE4B 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.